Results 101 to 110 of about 6,459 (257)

A real-world disproportionality analysis of tirzepatide-related adverse events based on the FDA Adverse Event Reporting System (FAERS) database

Endocrine Journal
Tirzepatide is a novel drug for the treatment of type 2 diabetes mellitus and chronic weight management, and there is an urgent need to explore its safety profile.
Jie Li, Jun Xie, Yi Han, Wei Zhang, Yilei Wang, Zhitao Jiang   +5 more
doaj   +1 more source

Tirzepatide for Obesity in Adults ≥ 65 Years: A Post Hoc Analysis of the SURMOUNT and SUMMIT Clinical Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Tirzepatide is a once‐weekly glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonist (RA) approved for weight management in adults with obesity. Data on older adults remain limited, however. This study aimed to examine tirzepatide's safety and efficacy in adults aged ≥ 65 years with obesity ...
Nasreen Alfaris, Robert F. Kushner, Jianghao Li, Kevin L. Chen, Mia Fenimore, Boris Calderon, Adam Stefanski   +6 more
wiley   +1 more source

Tirzepatide: A Review in Type 2 Diabetes

Declarations Funding The preparation of this review was not supported by any external funding. Authorship and Conflict of interest N.L. France and Y. Y.
Nicole L. France (17556397), Yahiya Y. Syed (6594444)   +1 more
core   +1 more source

Weight Drop - Foot Drop: A Case Series of Peroneal Nerve Palsy from Leg Crossing after Tirzepatide-mediated Weight Loss

Case Reports in Neurology
Introduction: Common peroneal nerve palsy, termed “Slimmer’s Palsy,” is a recognized complication of rapid weight loss. This case report describes two patients who developed foot drop following tirzepatide-induced weight loss precipitated by ...
Ann I. Tanyous, Jacob Oren Levitt
doaj   +1 more source

Effects of Incretin‐Based Therapies, Diet and Exercise Interventions, and Bariatric Surgery on Fat‐Free Mass in Adults With Overweight or Obesity: A Systematic Review and Meta‐Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Maintaining fat‐free mass (FFM) during weight loss is important to maintain a healthy body composition. This review examined changes in FFM during weight loss induced by diet and exercise interventions, incretin‐based therapies, and bariatric surgery, and assessed whether the relative loss of FFM differs by weight‐loss modality ...
Laura Busk‐Cirera, Ida Ørum Carlsen, Lærke Bruun Madsen, Rasmus Michael Sandsdal, Emma Jensen, Simon Birk Kjær Jensen, Signe Sørensen Torekov   +6 more
wiley   +1 more source

Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Adults With Type 2 Diabetes

Background: The comparative gastrointestinal safety across glucagon-like peptide-1 receptor agonists and tirzepatide is still unclear. Objective: To compare the risk for severe gastrointestinal adverse events across dulaglutide, subcutaneous semaglutide,
Glynn, Robert J, Alkabbani, Wajd, Paik, Julie M, Wexler, Deborah J, Patorno, Elisabetta, Crisafulli, Salvatore, Yu, Elaine W, Trifirò, Gianluca, Bykov, Katsiaryna, Tavakkoli, Ali, Htoo, Phyo T   +10 more
core   +1 more source

Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT‐1 and SURMOUNT‐2 Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Obesity affects over 800 million people globally and is associated with complications including cardiovascular disease and type 2 diabetes (T2D). Early response to weight loss interventions may help optimize achievement of individual treatment goals.
Alexander Kokkinos, Tina Thethi, Clare J. Lee, Lisa M. Neff, Adam Stefanski, Dachuang Cao, Angel Rodriguez, Amy Bartee   +7 more
wiley   +1 more source

Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity [PDF]

BACKGROUND: Obstructive sleep apnea is characterized by disordered breathing during sleep and is associated with major cardiovascular complications; excess adiposity is an etiologic risk factor. Tirzepatide may be a potential treatment.
Fietze, Ingo, Schwab, Richard J, Azarbarzin, Ali, Dunn, Julia P, Bunck, Mathijs C, Weaver, Terri E, Grunstein, Ronald R, Chakladar, Sujatro, Redline, Susan, Malhotra, Atul, Sands, Scott A, Bednarik, Josef   +11 more
core   +1 more source

Cost‐Effectiveness of Pharmacologic Therapies for Metabolic Dysfunction–Associated Steatohepatitis With Significant Fibrosis in the United States

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The approval of new pharmacotherapies for metabolic dysfunction‐associated steatohepatitis (MASH) presents a critical need for value assessment. We evaluated the cost‐effectiveness of resmetirom, semaglutide and tirzepatide for U.S. adults with MASH and F2–F3 fibrosis.
Ali A. Abdeen, Turgay Ayer, Aanan Biswas, Chase J. Wehrle, Sobia N. Laique, Ali Aminian   +5 more
wiley   +1 more source

An observational study of cardiovascular outcomes of tirzepatide vs glucagon-like peptide-1 receptor agonists [PDF]

Background: While cardiovascular benefits of tirzepatide, a glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes mellitus (T2DM), and its comparative effectiveness vs glucagon-like peptide-1 ...
Khadke, Sumanth, Fonarow, Gregg, Ganatra, Sarju, Al-Kindi, Sadeer, Nasir, Khurram, Nohria, Anju, Sattar, Naveed, Makwana, Bhargav, Kosiborod, Mikhail N., Butler, Javed, Kumar, Ashish, Dani, Sourbha S., Jhund, Pardeep, Bhatt, Deepak L.   +13 more
core   +1 more source